ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
21 announcements
Kwality Pharmaceuticals has regularized the appointment of Mr. Swanith Kapoor as Independent Director and reappointed Mr. Aditya Arora as Whole Time Director for five years.
Kwality Pharmaceuticals Limited conducted its 43rd Annual General Meeting on August 31, 2026, via video conferencing. The meeting covered routine shareholder resolutions and director re-appointments.
Kwality Pharma Q1FY27 con-call highlights revision of FY27 revenue target to ₹700Cr+ with 26-27% EBITDA margins, driven by niche injectable registrations in LATAM and MENA regions.
Kwality Pharma reported strong Q1FY27 performance with revenue up 45.7% YoY. Management raised FY27 revenue guidance to INR 700+ Cr and improved margin outlook.
Kwality Pharmaceuticals Ltd reported revenue from operations of ₹162.4 Cr (+45.7% YoY) and net profit of ₹25.6 Cr (+115.1% YoY) for Q1 FY27.
Kwality Pharmaceuticals Limited has announced the closure of its share transfer books from August 25, 2026, to August 31, 2026, for its 43rd Annual General Meeting.
Kwality Pharmaceuticals Limited has announced its 43rd Annual General Meeting, scheduled to be held on August 31, 2026, through video conferencing.
Kwality Pharmaceuticals approved its 43rd AGM notice and book closure dates. The board also approved director re-appointments and the appointment of cost auditors.
Kwality Pharmaceuticals will hold a board meeting on August 10, 2026, to consider and approve the standalone and consolidated unaudited financial results for the quarter ended June 30, 2026.
Kwality Pharmaceuticals received CDSCO approval to manufacture pilot batches of Pembroluzimab. This progresses the biologics product from research to the pre-clinical stage.
Kwality Pharmaceuticals Ltd has filed its quarterly shareholding pattern under SEBI Regulation 31(1)(b) for the quarter ended June 30, 2026.
Kwality Pharmaceuticals appointed Mr. Swanith Kapoor as an Independent Director for five years. Simultaneously, Mr. Kartik Kapur resigned from the board due to professional commitments.
Kwality Pharmaceuticals submitted its Annual Secretarial Compliance Report for FY 2025-26. The auditor confirmed general compliance with SEBI regulations with no new penalties reported.
Kwality Pharmaceuticals delivered a landmark FY26 with 36% revenue growth and 69% PAT growth, driven by higher-margin oncology products and improved operational efficiencies.
Kwality Pharmaceuticals delivered strong FY26 performance with ₹503 Cr revenue and ₹67 Cr PAT, driven by regulated market expansion and 4/5 EU-GMP approved units.
Kwality Pharmaceuticals Ltd reported revenue from operations of ₹157.1 Cr (+35.8% YoY) and net profit of ₹25.3 Cr (+74.5% YoY) for Q4 FY26.
Kwality Pharmaceuticals reported consolidated annual revenue of ₹503.08 Crore for FY26. Net profit stood at ₹67.35 Crore, reflecting strong operational growth and margin expansion.
Kwality Pharmaceuticals will hold a board meeting on May 19, 2026, to approve audited financial results. The trading window remains closed until May 21, 2026.
ICRA upgraded Kwality Pharmaceuticals' credit ratings to [ICRA]BBB+ (Stable)/[ICRA]A2 for ₹200.0 Crore facilities. The company was also removed from the Issuer Not Cooperating category.
Kwality Pharmaceuticals Ltd confirmed it does not meet the SEBI criteria for identification as a Large Corporate as of March 31, 2026. The company reported outstanding borrowings of ₹28.47 Crore and maintains a BBB credit rating from ICRA Limited. This disclosure is a routine regulatory compliance filing regarding debt-raising frameworks.
Kwality Pharmaceuticals Ltd submitted a compliance certificate under SEBI Regulation 74(5) for the quarter ended March 31, 2026. The Registrar and Share Transfer Agent, Bigshare Services, confirmed that securities received for dematerialization were processed, mutilated, and cancelled as per regulatory requirements.